An AI-derived digital pathology-based biomarker to predict the benefit of ADT in PC with validation in NRG/RTOG 9408

SG in combination with pembro in patients with mUC who progressed after platinum (PLT)-based regimens

NMIBC treated with IL-15RαFc superagonist N-803 and BCG infusion

Evaluating a polygenic hazard score to predict risk of developing metastatic or fatal prostate cancer

Atezolizumab with or without radiotherapy for advanced squamous cell carcinoma of the penis

Update: Cabozantinib plus nivolumab demonstrates continued survival benefit in aRCC

KEYNOTE 564 update: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma

ASCO GU 2022: What to watch out for in renal

Maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma

First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study.

Durvalumab with olapirib shows no PFS improvement for platinum-ineligible bladder cancer